Reshape Lifesciences® Expands US Market Presence With Innovative Neurorehabilitation Technology
$RSLS
ReShape Lifesciences® (Nasdaq:RSLS), a leading provider of weight loss and metabolic health solutions, has recently announced a significant expansion into the US neurorehabilitation market. This strategic move comes through a partnership with Motion Informatics, a company based in Haifa, Israel, known for its advanced neuromuscular rehabilitation devices. The collaboration is set to introduce the Stimel-03, a state-of-the-art system, to the American market.
Paul F. Hickey, President and CEO of ReShape Lifesciences, highlighted the importance of this partnership, stating, “This agreement with Motion Informatics is a pivotal step for ReShape as we broaden our portfolio into the rehabilitation technology space.” The Stimel-03 integrates multiple technologies such as Functional Electrical Stimulation (FES), Neuromuscular Electrical Stimulation (NMES) and real-time electromyographic (EMG) biofeedback into a single platform, offering a comprehensive solution for patients recovering from strokes, injuries, or surgeries.
In addition to the Stimel-03, the partnership will introduce the Spatial StimelMD (SSMD), a next-generation platform that combines AI-personalized neuromodulation, real-time EMG biofeedback and augmented reality. This platform is designed to adapt in real-time to a patient’s performance, fatigue and recovery, offering a tailored therapeutic process that can be administered in clinics, at home, or via telemedicine. ReShape Lifesciences is not only diversifying its product offerings but also reinforcing its commitment to addressing comprehensive health challenges.
The company continues to support weight loss and metabolic health through its FDA-approved Lap-Band® System and is developing the investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system aimed at treating type 2 diabetes. This strategic expansion into neurorehabilitation aligns with ReShape Lifesciences’ mission to enhance patient outcomes and build on its reputation as a leader in healthcare innovation.
**DISCLAIMER: THIS CONTENT IS FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE INTERPRETED AS INVESTMENT ADVICE. INVESTING INVOLVES RISK, INCLUDING THE POTENTIAL LOSS OF PRINCIPAL. READERS ARE ENCOURAGED TO CONDUCT THEIR OWN RESEARCH AND CONSULT WITH A QUALIFIED FINANCIAL ADVISOR BEFORE MAKING ANY INVESTMENT DECISIONS.**
